Sponsored Links
| Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles Of Treatment For Cystic Fibrosis Patients With Pseudomonas Lung Infections |
 |
 |
 |
| Pharmacy - Pharma Industry - Biotech Industry | |||
|
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced positive data through six treatment cycles (72 weeks total duration) of its Phase 2 clinical trial program for ARIKACE® (liposomal amikacin for inhalation) in cystic fibrosis (CF) patients with Pseudomonas lung infections... Read more: Pharma Industry / Biotech Industry News From Medical News Today
|